TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16317380

Group type: EXPERIMENTAL
Intervention: Hyperdynamic left ventricular function (LVF) as assessed by echocardiography (ejection fraction >55%)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 103
Study: 12818934

Group type: EXPERIMENTAL
Intervention: Intrathecal opioid (1 micro g/kg sufentanil with 8 micro g/kg preservative-free morphine)
Number of subjects: 217

Group type: COMPARATOR
Intervention: General anesthesia alone (control)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Intrathecal opioid
Number of subjects: 217
Study: 10985008

Group type: EXPERIMENTAL
Intervention: Interdisciplinary prevention program (theater program)
Number of subjects: 301
Study: 8791955

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.d. plus amoxycillin 1 g b.d.
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg b.d. plus amoxycillin 1 g b.d.
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Omeprazole 80 mg b.d. plus amoxycillin 1 g b.d.
Number of subjects: 231
Study: 1536485

Group type: EXPERIMENTAL
Intervention: 2 g i.v. magnesium sulfate infused over 20 minutes
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no magnesium)
Number of subjects: 120
Study: 6142700

Group type: EXPERIMENTAL
Intervention: H2 receptor antagonist cimetidine in combination with H1 receptor antagonist chorpheniramine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Chlorpheniramine alone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30878435

Group type: COMPARATOR
Intervention: CAC scores of 0
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: CAC scores >0 to 100
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: CAC scores >100 to 300
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: CAC scores >300
Number of subjects: 1205
Study: 31166681

Group type: EXPERIMENTAL
Intervention: Venetoclax-obinutuzumab
Number of subjects: 432

Group type: COMPARATOR
Intervention: Chlorambucil-obinutuzumab
Number of subjects: 432
Study: 28095827

Group type: EXPERIMENTAL
Intervention: Physical activity intervention for smoking cessation during pregnancy
Number of subjects: 0
Study: 25293431

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (n=18)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Soy protein supplementation (n=21)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (n=22)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Overall cohort (all groups combined)
Number of subjects: 61
Study: 23507474

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 17
Study: 20732932

Group type: EXPERIMENTAL
Intervention: AP-D (pemetrexed 500 mg/m² plus doxorubicin 60 mg/m² every 3 weeks followed by docetaxel 100 mg/m² every 3 weeks)
Number of subjects: 257

Group type: COMPARATOR
Intervention: AC-D (doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² every 3 weeks followed by docetaxel 100 mg/m² every 3 weeks)
Number of subjects: 257
Study: 19916712

Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac sodium at a dose of 2 x 75 mg and additional breakthrough meperidine at 50 mg dosages if necessary
Number of subjects: 130

Group type: COMPARATOR
Intervention: Meperidine 6 x 50 mg
Number of subjects: 130
Study: 17029608

Group type: EXPERIMENTAL
Intervention: Intermittent pedaling (5 min with 3-min rest intervals at 40 rpm and 0.15 kp load)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Rest (as control)
Number of subjects: 8
Study: 12682802

Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg four times daily for 7 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 11052428

Group type: EXPERIMENTAL
Intervention: Fluid-filled warming blanket (Group 1, n = 33)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Heated and humidified breathing circuit (Group 2, n = 31)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Intravenous fluid warmers (Group 3, n = 37)
Number of subjects: 101
Study: 9261942

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (A/Yamagata/32/89, A/Beijing/352/89, B/Bangkok/163/90)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (A/Beijing/352/89)
Number of subjects: 0
Study: 8000795

Group type: EXPERIMENTAL
Intervention: Prostaglandin contents in gastric juice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 0
Study: 2883202

Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 31971338

Group type: EXPERIMENTAL
Intervention: IVUS-guided stenting strategy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Angiography-guided stenting
Number of subjects: 100
Study: 29233857

Group type: EXPERIMENTAL
Intervention: Eating late
Number of subjects: 10

Group type: COMPARATOR
Intervention: Eating early
Number of subjects: 10
Study: 27354084

Group type: EXPERIMENTAL
Intervention: Virtual Traveller intervention (10-min sessions, 3 days per week for 6 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 10
Study: 24385115

Group type: EXPERIMENTAL
Intervention: Clindamycin/tretinoin gel patches
Number of subjects: 95

Group type: COMPARATOR
Intervention: Vehicle gel patches
Number of subjects: 95

Group type: COMPARATOR
Intervention: Blank patches (no gel)
Number of subjects: 95
Study: 22428144

Group type: EXPERIMENTAL
Intervention: Lutein diacetate (20 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Crystalline lutein (20 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 20828487

Group type: EXPERIMENTAL
Intervention: Iso-strain work situation (high demands, low control, and low social support) among females
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Strained work situation (high demands, low control)
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Low social support combined with a passive work situation
Number of subjects: 532

Group type: COMPARATOR
Intervention: Iso-strain model
Number of subjects: 532
Study: 18430173

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (Restylane, 1.4 mL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Collagen (Cosmoplast, 2.0 cm³)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Number of subjects: 10

Group type: COMPARATOR
Intervention: Collagen
Number of subjects: 10
Study: 15888157

Group type: EXPERIMENTAL
Intervention: High-fluence laser treatment
Number of subjects: 88

Group type: COMPARATOR
Intervention: Low-fluence laser treatment (Control)
Number of subjects: 88
Study: 12552211

Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine (ITB) 37.5 mg
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (sham spinal)
Number of subjects: 38
Study: 10532441

Group type: EXPERIMENTAL
Intervention: Verteporfin (6 mg per square meter of body surface area) administered via intravenous infusion of 30 mL over 10 minutes.
Number of subjects: 609

Group type: COMPARATOR
Intervention: Placebo (5% dextrose in water) administered via intravenous infusion of 30 mL over 10 minutes.
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Verteporfin therapy for predominantly classic CNV lesions (area of classic CNV occupied 50% or more of the area of the entire lesion).
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Verteporfin treatment.
Number of subjects: 609

Group type: COMPARATOR
Intervention: Placebo treatment.
Number of subjects: 609
Study: 8828529

Group type: EXPERIMENTAL
Intervention: Oral corticosteroids (prednisone, median daily dose 20 mg, median duration 2 years)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (66 patients with asthma)
Number of subjects: 33
Study: 1795470

Group type: EXPERIMENTAL
Intervention: roxicam
Number of subjects: 51

Group type: COMPARATOR
Intervention: aspirin
Number of subjects: 51

Group type: COMPARATOR
Intervention: basic therapies (nitrates + cardiac glycosides + diuretics)
Number of subjects: 51
Study: 7031204

Group type: EXPERIMENTAL
Intervention: Dispersalloy (D)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Indiloy (I)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Experimental high copper amalgam (E)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Tytin (T)
Number of subjects: 435

Group type: COMPARATOR
Intervention: New True Dentalloy (N)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Aristaloy CR (A)
Number of subjects: 435
Study: 30368662

Group type: EXPERIMENTAL
Intervention: Gluma Bond Universal (GU) in self-etch mode
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Single Bond Universal (SU) in self-etch mode
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Prime&Bond Elect Universal (PU) in self-etch mode
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Clearfil Universal (CU) in self-etch mode
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: All Bond Universal (AU) in self-etch mode
Number of subjects: 42

Group type: COMPARATOR
Intervention: etch-and-rinse mode (all adhesives)
Number of subjects: 42
Study: 29145309

Group type: EXPERIMENTAL
Intervention: Rigid taping (RT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-taping (NT)
Number of subjects: 24
Study: 26474055

Group type: EXPERIMENTAL
Intervention: Nurse-led, telephone-based follow-up
Number of subjects: 537

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 537
Study: 25063274

Group type: EXPERIMENTAL
Intervention: Intramuscular glucagon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hyperinsulinaemic hypoglycaemia testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hyperinsulinaemic-euglycaemic conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucagon treatment in isolated rat pancreatic islets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazoxide exposure in pancreatic islets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anti-insulin antibody exposure in pancreatic islets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucagon treatment in islets pretreated with diazoxide or anti-insulin antibody
Number of subjects: 0
Study: 17761454

Group type: EXPERIMENTAL
Intervention: Videotape-assisted questionnaire (VQ)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard questionnaire (SQ)
Number of subjects: 108
Study: 14725866

Group type: EXPERIMENTAL
Intervention: Smokers with panic disorder (PD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsmokers with panic disorder (PD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Smokers without panic disorder (PD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsmokers without panic disorder (PD)
Number of subjects: 0
Study: 11401111

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study: 9334525

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8231773

Group type: EXPERIMENTAL
Intervention: Leg cycle ergometry
Number of subjects: 26

Group type: COMPARATOR
Intervention: Weight training
Number of subjects: 26
Study: 2446132

Group type: EXPERIMENTAL
Intervention: Immediate adjuvant cisplatin‐based chemotherapy
Number of subjects: 195

Group type: COMPARATOR
Intervention: Observation with treatment at relapse
Number of subjects: 195
Study: 11315838

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 21

Group type: COMPARATOR
Intervention: Regular insulin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Postprandial MG and 3‐DG
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Postprandial D‐lactate
Number of subjects: 21
Study: 29398169

Group type: EXPERIMENTAL
Intervention: Respiratory muscle training program adjusted to 50% of maximal inspiratory pressure, in addition to standard care.
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard care of respiratory physiotherapy (Control group).
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Respiratory muscle training program.
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control).
Number of subjects: 126
Study: 29960605

Group type: EXPERIMENTAL
Intervention: Tailored activity counselling intervention (IG) encouraging to increase daily step count by 5%
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both groups (IG and CG)
Number of subjects: 65
Study: 26822326

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control for a mean of 3.7 years
Number of subjects: 8601

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control during active phase
Number of subjects: 8601

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control during prolonged follow-up
Number of subjects: 8601
Study: 25009220

Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE) - single, unilateral bout using knee extensors (four sets of 10 repetitions at 75% of one repetition maximum on leg press and leg extension)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE)
Number of subjects: 18
Study: 22367658

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 mg/d for 7 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/d for 7 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg/d for 7 days)
Number of subjects: 12
Study: 19946887

Group type: EXPERIMENTAL
Intervention: Zomba Cash Transfer Program (CCT) providing US$10/month and payment of secondary school fees
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 17096672

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study: 15608524

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/rtv) 400/100 mg BID plus nevirapine (NVP) 200 mg BID (NVP group, n = 16)
Number of subjects: 31

Group type: COMPARATOR
Intervention: lopinavir/ritonavir (LPV/rtv) plus the 2 previous NRTIs (NRTI group, n = 15)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: NVP group
Number of subjects: 31

Group type: COMPARATOR
Intervention: NRTI group
Number of subjects: 31
Study: 11857093

Group type: EXPERIMENTAL
Intervention: E2 and Prog replacement
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 10100042

Group type: EXPERIMENTAL
Intervention: Essential oil mouthrinse (Listerine Antiseptic)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Amine fluoride/stannous fluoride mouthrinse (Meridol)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Chlorhexidine mouthrinse (Chlorhexamed‐Fluid)
Number of subjects: 23
Study: 7752332

Group type: EXPERIMENTAL
Intervention: Unilateral ligation of the right spermatic vein
Number of subjects: 65

Group type: COMPARATOR
Intervention: Bilateral ligation of the spermatic veins
Number of subjects: 65
Study: 2401128

Group type: EXPERIMENTAL
Intervention: Fast infusion of felodipine (plasma concentration of 6 ng/ml after 20 minutes, sustained for 8 hours)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Slow infusion of felodipine (plasma concentration of 6 ng/ml after 8 hours)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control infusions with saline and vehicle
Number of subjects: 8
Study: 399250

Group type: EXPERIMENTAL
Intervention: Cefaclor (3 x 500 mg)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Amoxicillin (3 x 750 mg)
Number of subjects: 110
Study: 31393158

Group type: EXPERIMENTAL
Intervention: Judgments of soldiers' actions influenced by the justness of their causes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implicit presumption that soldiers identify with their cause
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alignment with the just side of a war
Number of subjects: 0
Study: 31272212

Group type: COMPARATOR
Intervention: Fortified rice with 0 gm lime per 500 gm of rice
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Fortified rice with 2.5 gm lime per 500 gm of rice
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Fortified rice with 5 gm lime per 500 gm of rice
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Fortified rice with 7.5 gm lime per 500 gm of rice
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Fortified rice with 10 gm lime per 500 gm of rice
Number of subjects: 400
Study: 28836984

Group type: EXPERIMENTAL
Intervention: Intervention group (received 4 weeks training on adolescent sexuality topics)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 145
Study: 26395834

Group type: EXPERIMENTAL
Intervention: CT-P13 (5 mg/kg)
Number of subjects: 213

Group type: COMPARATOR
Intervention: EU-RMP (5 mg/kg)
Number of subjects: 213

Group type: COMPARATOR
Intervention: US-RMP (5 mg/kg)
Number of subjects: 213
Study: 23356839

Group type: EXPERIMENTAL
Intervention: PhysioDirect
Number of subjects: 2249

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2249
Study: 21629997

Group type: COMPARATOR
Intervention: Acute nicotine (2 mg gum) in non-smokers
Number of subjects: 48

Group type: COMPARATOR
Intervention: Chronic nicotine use in temporarily abstaining smokers
Number of subjects: 48
Study: 19568199

Group type: EXPERIMENTAL
Intervention: Before‐Meals exercise (2 hours of treadmill exercise at 43% of maximal effort)
Number of subjects: 9

Group type: COMPARATOR
Intervention: After‐Meals exercise (2 hours of treadmill exercise at 43% of maximal effort)
Number of subjects: 9
Study: 17584560

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 1357

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 1357

Group type: COMPARATOR
Intervention: Telmisartan vs Placebo
Number of subjects: 1357

Group type: EXPERIMENTAL
Intervention: Combination of Telmisartan and Ramipril
Number of subjects: 1357
Study: 15035520

Group type: EXPERIMENTAL
Intervention: Stereotactically guided core biopsy (SCB)
Number of subjects: 2403

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided core biopsy (USCB)
Number of subjects: 2403

Group type: EXPERIMENTAL
Intervention: Core biopsy (CB)
Number of subjects: 2403

Group type: EXPERIMENTAL
Intervention: Core biopsy (CB) for masses
Number of subjects: 2403

Group type: EXPERIMENTAL
Intervention: Core biopsy (CB) for calcifications
Number of subjects: 2403

Group type: EXPERIMENTAL
Intervention: Core biopsy (CB) for DCIS
Number of subjects: 2403

Group type: EXPERIMENTAL
Intervention: Core biopsy (CB) for invasive cancer
Number of subjects: 2403
Study: 11160540

Group type: EXPERIMENTAL
Intervention: Solid fat rich in lauric acid (Sat-diet)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Solid fat rich in trans-fatty acids (trans-diet)
Number of subjects: 32
Study: 9734742

Group type: EXPERIMENTAL
Intervention: Beta-carotene (50 mg/d)
Number of subjects: 259
Study: 7853324

Group type: COMPARATOR
Intervention: Standard cuff (23 x 12 cm)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Large cuff (34 x 15 cm)
Number of subjects: 50
Study: 3058132

Group type: EXPERIMENTAL
Intervention: Spironolactone (100-200 mg/d)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Potassium canrenoate (50-200 mg/d)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 54
Study: 31854119

Group type: EXPERIMENTAL
Intervention: 2-octyl cyanoacrylate (OCA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 70
Study: 30342298

Group type: EXPERIMENTAL
Intervention: Pemafibrate (0.2 mg twice daily)
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 10000
Study: 28179438

Group type: EXPERIMENTAL
Intervention: Telemonitoring programme
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard management
Number of subjects: 100
Study: 26230869

Group type: EXPERIMENTAL
Intervention: External-focus feedback
Number of subjects: 28

Group type: COMPARATOR
Intervention: Internal-focus feedback
Number of subjects: 28
Study: 23978276

Group type: EXPERIMENTAL
Intervention: Barber-assisted intervention with referrals to hypertension specialists
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Barber-assisted intervention with referrals to primary care providers (PCPs)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Comparison group (pamphlet only)
Number of subjects: 138
Study: 21789744

Group type: EXPERIMENTAL
Intervention: WAVCNS index
Number of subjects: 24
Study: 18213545

Group type: EXPERIMENTAL
Intervention: Quercetin (1000 mg/day for 3 weeks before, during, and 2 weeks after the race)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 16363014

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 62

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 62
Study: 12743146

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg daily)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 10985706

Group type: EXPERIMENTAL
Intervention: Early revascularization
Number of subjects: 1190

Group type: COMPARATOR
Intervention: Thrombolytic therapy and/or intra-aortic balloon counter-pulsation, coronary angiography, angioplasty and/or coronary artery bypass surgery
Number of subjects: 1190

Group type: COMPARATOR
Intervention: Ventricular septal rupture
Number of subjects: 1190

Group type: COMPARATOR
Intervention: Registry patients managed with various treatments
Number of subjects: 1190
Study: 9173382

Group type: EXPERIMENTAL
Intervention: Coumarin
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Coumarin plus low-dose acetylsalicylic acid (125 mg/day)
Number of subjects: 296
Study: 8255126

Group type: EXPERIMENTAL
Intervention: Dipyrone 1 g
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Dipyrone 2 g
Number of subjects: 129

Group type: COMPARATOR
Intervention: Diclofenac sodium 75 mg
Number of subjects: 129
Study: 3993547

Group type: EXPERIMENTAL
Intervention: Propranolol (nonselective beta-blocker)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Atenolol (cardioselective beta-blocker)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31595300

Group type: EXPERIMENTAL
Intervention: PA-only intervention
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: PA+FSM intervention
Number of subjects: 208

Group type: COMPARATOR
Intervention: Contact-control intervention (CC)
Number of subjects: 208